Enliven 制药

最新新闻

• Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• J.P. Morgan Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $62
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• Morgan Stanley Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  William Blair Initiates Enliven Therapeutics(ELVN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• Morgan Stanley Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $45 to $80
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70
  \u5e02\u573a\u8d44\u8baf · 2026/6/29
• 评级变动
  Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $59
  \u5e02\u573a\u8d44\u8baf · 2026/6/6
• 评级变动
  Stifel Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/6/9
• 评级变动
  LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $80
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• Barclays Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $78
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/13

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。